Article

Association of rapidly progressive moyamoya syndrome with bevacizumab treatment for glioblastoma in a child with neurofibromatosis type 1.

Department of Neurology, Children's Hospital Boston, Boston, MA 02446, USA.
Journal of child neurology (impact factor: 1.59). 02/2011; 26(2):228-30. DOI:10.1177/0883073810379639
Source: PubMed

ABSTRACT Neurofibromatosis type 1 is a common multisystemic disorder that can result in tumors of the central and peripheral nervous system. Individuals with neurofibromatosis type 1 are also at increased risk to develop moyamoya syndrome, which is a cerebrovascular condition that predisposes affected individuals to develop strokes as a result of progressive narrowing of the intracranial internal carotid arteries and failure of adequate blood supply through collateral vessels. We report a case of a young boy with neurofibromatosis type 1 with glioblastoma who developed rapidly progressive moyamoya vasculopathy after treatment with the angiogenesis inhibitor bevacizumab.

0 0
 · 
0 Bookmarks
 · 
31 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

adequate blood supply
 
angiogenesis inhibitor bevacizumab
 
central
 
cerebrovascular condition
 
common multisystemic disorder
 
intracranial internal carotid arteries
 
neurofibromatosis type 1
 
peripheral nervous system
 
progressive moyamoya vasculopathy
 
strokes
 
young boy